Gain Therapeutics, Inc. (GANX)

NASDAQ: GANX · IEX Real-Time Price · USD
4.33
0.29 (7.18%)
At close: Jan 25, 2022 3:59 PM
4.32
-0.01 (-0.23%)
After-hours:Jan 25, 2022 5:12 PM EST
Market Cap51.44M
Revenue (ttm)130,926
Net Income (ttm)-12.33M
Shares Out11.88M
EPS (ttm)-1.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,723
Open3.90
Previous Close4.04
Day's Range3.90 - 4.41
52-Week Range3.80 - 17.93
Betan/a
AnalystsStrong Buy
Price Target27.00 (+523.6%)
Earnings Daten/a

About GANX

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B,...

IndustryBiotechnology
IPO DateMar 18, 2021
Employees11
Stock ExchangeNASDAQ
Ticker SymbolGANX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price forecast is 27.00, which is an increase of 523.56% from the latest price.

Price Target
$27.00
(523.56% upside)
Analyst Consensus: Strong Buy

News

Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference

BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never b...

2 weeks ago - GlobeNewsWire

Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BETHESDA, Md., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites...

4 weeks ago - GlobeNewsWire

Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update

Data Show Statistically Significant Increases in GALC Enzyme and Depletion of Toxic Substrate Psychosine Data Show Statistically Significant Increases in GALC Enzyme and Depletion of Toxic Substrate Psy...

1 month ago - GlobeNewsWire

Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit

BETHESDA, Md., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never b...

1 month ago - GlobeNewsWire

Gain Therapeutics Presents Parkinson's Disease Preclinical Study Results at Society for Neuroscience Annual Meeting

Brain-penetrant structurally targeted allosteric regulators for glucocerebrosidase (GCase) show promising in vivo pharmacological activity in Parkinson's Disease animal model Brain-penetrant structurall...

2 months ago - GlobeNewsWire

Gain Therapeutics Stock Surges On Positive Preclinical Readout For Neurodegenerative Disease Drugs

Gain Therapeutics, Inc. (NASDAQ: GANX) shares were trading higher Wednesday after the company presented positive data on two of its lead compounds. What Happened: Bethesda, Maryland-based Gain announced...

2 months ago - Benzinga

Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data of Novel Small Molecules for the Treatment of Parkin...

Study results demonstrate first small molecule approach to significantly reduce phosphorylated and aggregated -synuclein and increase GCase protein levels  with transport to the lysosomes in iPSC dopami...

2 months ago - GlobeNewsWire

Gain Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference

In-Person Dates: November 16 th -17 th Virtual Dates: November 18 th -19 th

2 months ago - GlobeNewsWire

Gain Therapeutics to Present at Upcoming Medical Conferences

- The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Webinars -

2 months ago - GlobeNewsWire

Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB)

Dr. Luca Benatti to Chair SAB Dr. Luca Benatti to Chair SAB

2 months ago - GlobeNewsWire

Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer

BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites...

3 months ago - GlobeNewsWire

Gain Therapeutics' SEE-Tx™ Platform Shows Increasing Evidence in Treating Diseases Caused by Protein Misfolding

Image by National Cancer Institute on Unsplash Medical and technological advancements are extending our lifespan. Unfortunately, as human life expectancy rises, so does the risk of people developing a d...

3 months ago - Benzinga

Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

Conference Dates: September 27th-30th Conference Dates: September 27th-30th

4 months ago - GlobeNewsWire

Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

- Conference Dates: September 20 th -23 rd -

4 months ago - GlobeNewsWire

Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference

BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding site...

4 months ago - GlobeNewsWire

Why Gain Therapeutics Shares Are Trading Higher Today

Gain Therapeutics Inc (NASDAQ: GANX) are trading higher Wednesday after the company announced positive topline data in a patient-derived iPSC study evaluating STAR compounds as a treatment for Gaucher a...

4 months ago - Benzinga

Gain Therapeutics' Gaucher, Parkinson's Candidate Shows Potential In Patient-Derived iPSC Study

The topline data from a study conducted at the University of Maryland School of Medicine (UMSOM) by Gain Therapeutics Inc (NASDAQ: GANX) evaluating two lead Structurally Targeted Allosteric Regulators (...

4 months ago - Benzinga

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a ...

GT-02287and GT-02329 compounds display positive effects on GCase activity  and related parameters ---  Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and d...

4 months ago - GlobeNewsWire

Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding site...

4 months ago - GlobeNewsWire

Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update

Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology --- Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathie...

5 months ago - GlobeNewsWire

Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference

BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel alloste...

5 months ago - GlobeNewsWire

Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment o...

Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lys...

7 months ago - GlobeNewsWire

Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference

BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bin...

7 months ago - GlobeNewsWire

Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May

BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bin...

8 months ago - GlobeNewsWire

Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results

Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collab...

8 months ago - GlobeNewsWire